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GeneticsAccurate diagnosis of predisposition to long QT syndrome is crucial for reducing the risk of cardiac arrhythmias.
In recent years, drug-induced provocative tests have proved useful to unmask some latent mutations linked to
cardiac arrhythmias. In this study we expanded this concept by developing a prototype for a computational
provocative screening test to reveal genetic predisposition to acquired long-QT syndrome (aLQTS). We devel-
oped a computational approach to reveal the pharmacological properties of IKr blocking drugs that aremost likely
to cause aLQTS in the setting of subtle alterations in IKr channel gating that would be expected to result from be-
nign genetic variants.Weused themodel to predict themost potentially lethal combinations of kinetic anomalies
and drug properties. In doing so, we also implicitly predicted ideal inverse therapeutic properties of K channel
openers that would be expected to remedy a speciﬁc defect. We systematically performed “in silicomutagenesis”
by altering discrete kinetic transition rates of the Fink et al. Markov model of human IKr channels, corresponding
to activation, inactivation, deactivation and recovery from inactivation of IKr channels. We then screened and
identiﬁed the properties of IKr blockers that caused acquired long QT and therefore unmasked mutant phenotypes
formild,moderate and severe variants. Mutant IKr channelswere incorporated into theO'Hara et al. human ventric-
ular action potential (AP)model and subjected to simulated application of a wide variety of IKr–drug interactions in
order to identify the characteristics that selectively exacerbate theAPduration (APD) differences betweenwild-type
and IKr mutated cells. Our results show that drugs with disparate afﬁnities to conformation states of the IKr channel
are key to amplify variants underlying susceptibility to acquired long QT syndrome, an effect that is especially
pronounced at slow frequencies. Finally, we developed a mathematical formulation of the M54T MiRP1 latent
mutation and simulated a provocative test. In this setting, application of dofetilide dramatically ampliﬁed the
predicted QT interval duration in the M54T hMiRP1 mutation compared to wild-type.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Drug-induced or acquired long-QT syndrome (aLQTS) is a disorder
characterized by abnormally prolonged ventricular repolarizationT syndrome;AP, actionpotential;
ration at 90% repolarization; C1,
ly-afterdepolarization; ECG, elec-
of the delayed rectiﬁer current;
m inactivation; TdP, torsade de
aneously to both the open and
_Oi, drug binding simultaneous-
ty to the open state; Actilide_Co,
states with higher afﬁnity to the
both the inactivated and open
fax: +34 96 3877093.
nor@eln.upv.es (B. Trenor),
iz), ceclancy@ucdavis.edusecondary to drug application that can lead to potentially lethal arrhyth-
mias, such as torsade de pointes (TdP) [1]. This side-effect has resulted
in black box warnings limiting the use of many drugs intended for
treatment of cardiac dysrhythm, psychiatric disorders, gastrointestinal
symptoms and infection [2] (http://www.qtdrugs.org). Drugs have even
been removed from the market due to unintended effects on cardiac
repolarization [3].
Because the rapidly activating component of the cardiac delayed
rectiﬁer current (IKr) arising from the gene hERG is a well-known pro-
miscuous drug target, there has been deliberate focus on the off-target
drug effects on hERG. Importantly, susceptibility to aLQTS has been
linked to normally benign DNA variants in the genes encoding hERG
and its ancillary subunits that modify risk to aLQTS and arrhythmias
[1,4,5]. Indeed, approximately 15% of patients with aLQTS have been
shown to exhibit allelic variants in coding regions of genes linked to
congenital forms of long-QT syndrome (LQTS) [5].
Accurate identiﬁcation of individualswho are susceptible to aLQTS is
crucial for reducing the risk of cardiac arrhythmias [6]. Unfortunately,
diagnosis based on baseline QT interval is not deﬁnitive [7] and genetic
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decade, drug-induced provocative tests have been proposed to unmask
some types of latent mutation carriers. These provocative tests consist
of the addition of a drug that uncovers an otherwise concealed disease.
During the provocative test, the functional effects of a presumed defec-
tive ion channel are ampliﬁed, leading to measurable alterations in the
electrocardiogram relative to changes observed with a normal channel.
For example, catecholamines, such as epinephrine, can be used to reveal
LQT1, which is due to IKs impairment [8], potent sodium blockers [9],
such as ﬂecainide, and also potent sodium blockers with calcium
blockers [10] have been used to unmask Brugada syndrome, and sotalol
[11] and erythromycycin [12], potent IKr blockers, have been shown to
uncover altered repolarization.
Here, we employed a mathematical modeling approach to take
existing tests a step further. We attempt to reveal the pharmacological
properties of IKr blocking drugs that not only reveal predisposition to
aLQTS, but also reveal the speciﬁc kinetic anomaly underlying the in-
creased risk. In doing so, we also implicitly predict ideal therapeutic
properties of K+ channel openers that would be expected to remedy
the defect. We systematically carried out “in silico mutagenesis” by
altering discrete kinetic transition rates corresponding to activation, in-
activation, deactivation and recovery from inactivation of IKr channels.
Our model predicts the most potentially lethal combinations of kinetic
abnormalities and drug properties. Moreover, it identiﬁes the speciﬁc
properties of an IKr blocker that most exacerbate mutant phenotypes
arising from speciﬁc defective IKr kinetics (activation, deactivation, inac-
tivation and recovery from inactivation). Such a test can be used to un-
mask the mutant phenotype for latent, mild, and moderate mutants.
Importantly, our method consists of a library of “off-the-shelf”mutant
and drug interaction templates that can be readily expanded to predict
drug interactions with any identiﬁed IKr mutation. To apply our ap-
proach in a true clinical setting, we carried out an in silico screen for
the naturally occurring hERG mutation, the M54T MiRP1 mutation,
which has been implicated in drug-induced LQTS and arrhythmia. We
used the model to propose a provocative test to unmask the M54T mu-
tation, which the model predicts will be most successful with a drug
binding simultaneously to both the open and closed states with higher
afﬁnity to the open state (Actilide_Oc) or a drug binding simultaneously
to both the open and inactivated states with higher afﬁnity to the open
state (Inactilide_Oi), dofetilide. We also predict that use of a potassium
channel opener as an adjunctive therapy can effectively blunt the effects
of dofetilide-induced action potential prolongation of theM54T hMiRP1
mutation. Finally, the inﬂuence of heart rate and the concomitant effects
of silent mutations in genes encoding other ionic currents were also
investigated.
2. Methods
The human ventricular IKr was simulated using the ﬁve-state
Markov chain proposed by Fink et al. [13]. Transition rate constants
are provided in the supplemental material (Table S1). The Fink IKr
Markov model was incorporated into the O'Hara et al. human ventricu-
lar action potential (AP)model [14] and its maximum conductancewas
scaled to elicit the same peak IKr value as the original O'Hara model at
1 Hz.
Activation (αα), deactivation (ββ), inactivation (αi) and recovery
from inactivation (βi) transition ratesweremodiﬁed to simulate genetic
defects altering the activation, deactivation, inactivation and recovery
from inactivation processes, respectively. In each case, transition rates
were scaled to produce a 10ms, 20ms and 50ms prolongation of action
potential duration at 90% repolarization (APD90) at 1 Hz, which gives
rise to 12 prototypical IKr mutations. Scale factors are provided in the
supplemental material (Table S2). Moreover, additional summative ef-
fects of IKs and INaL silent mutations were simulated by modifying the
slow component of the delayed rectiﬁer current (IKs) and the late sodi-
um current (INaL). IKs and INaL were independently scaled to produce a20 ms APD90 prolongation in WT cells. Then, all possible IKr mutants
were simulated alone or in addition to these IKs and INaL modiﬁcations
to simulate the combined effects of IKr, IKs and INaL silent mutations. A
total number of 38 prototypical mutants, namely, 12 IKr mutations, 12
IKr mutations combined with IKs reduction, 12 IKr mutations combined
with INaL increase, one IKs mutation alone and one INaL mutation alone,
were simulated.
The M54T hMiRP1 mutation was modeled using a modiﬁed
Nelder–Mead simplex method to modify the Markov model transi-
tion rates in the Fink IKr model by minimizing the sum of the least-
square errors between the experimental [4] and the simulated
steady state activation curves, steady state inactivation curves and
deactivation time constants. Then, to validate the M54T hMiRP1 mu-
tation computational model, the simulated reduction of current den-
sity at−40 mVwas compared to additional experimental results [1].
As experiments were performed at 22 °C [4] and room temperature
[1], temperature was exclusively ﬁxed to 22 °C to compare the sim-
ulated kinetics of the mutation to experiments. Physiological action
potential simulationswere subsequently performed at 37 °C. Rate tran-
sitions for WT and the mutated cells are available in the supplemental
material (Table S1).
In order to simulate known drug interactionswith IKr, we usedmea-
sured afﬁnities and drug diffusion rates used to constrain the drug “on”
and “off” rates. Diffusion rates (D) indicate drug on rates “k”= [drug] ∗
D and afﬁnities (Kd) to discrete conformations that determine drug off
rates “r” = Kd ∗ D. Association (k) and dissociation (r) rate values for
each IKr–drug interaction as tested in the model are in the supplement
(Table S3). On and off rates were varied in simulations of “theoretical”
drugs. A total number of 21 drug interactions with IKr were simulated;
dofetilide and 20 “theoretical drugs”. In addition, two potassium
channel openers, RPR260243 and a virtually designed “activator” drug
were simulated in some cases. In order to simulate the effects of
RPR260243 we used the same binding and unbinding rate constants
as Perry et al. [15] and activator bound channels were reconstructed
applying the same modiﬁcations as Perry and coworkers to the WT
channels, namely slowed deactivation, slowed activation and reduced
inactivation [15]. The model of the virtual activator resulted from elim-
inating the reduced inactivation from the RPR260243 model and was
called RPR260243_mod.
1596 provocative tests were carried out with the application of low
and high concentrations of each simulated drug toWT cells and to every
mutant at 1 Hz. For reproducibility, the low and high doses of a certain
drug was deﬁned as the drug concentration that produced the same
steady stateWTAPD90 prolongation as 16 nM(in linewith its therapeu-
tic dose [3]) and 48nMdofetilide, respectively. Lowdose values for each
simulated drug are available in the supplemental material (Table S3).
442 additional provocative tests were performed at 2 Hz and 0.67 Hz
by applying low doses of those drugs that most ampliﬁed the effects
of IKr mutants on ADP90 at 1 Hz to investigate the rate dependence of
aLQTS in genetically predisposed cells. Furthermore, as APD adaptation
to abrupt changes in pacing rate has been proposed as a clinical marker
for arrhythmic risk [16], APD rate adaptation was also characterized by
recording APD90 during the transition from the steady-state at 1 Hz to
1.7 Hz and from 1.7 Hz to 1 Hz after 10min of pacing at 1.7 Hz. This pro-
tocol is similar to that used in clinical and experimental studies [17,18]
and in other theoretical works [19,20]. APD90 dynamicswere character-
ized by the fast and slow time constants of the APD90 adaptation to
the accelerating and decelerating rate transitions (τfast_accelerating,
τslow_accelerating, τfast_decelerating and τslow_decelerating, respectively)
[19,20]. When the duration of APD adaptation was longer than 10 min,
independent prolongation of each transition was conducted to obtain
the slow time constants.
Action potential simulations were carried out in isolated endo-
cardial cells at 1 Hz and pseudo-ECGs were computed using a 1-
dimensional model of the transmural wedge preparation, as described
in [14].
Fig. 1.Dofetilide IKr block inWT and IKr mutant cells. Onset ofWT IKr block by 50 nMdofetilide (A, B) and 3 μMdofetilide washout (C), conductance voltage curves (E) and Hill plots (F) of
dofetilide-binding toWT, N588E-hERG and N588K-hERGmutants. In panels A–C, symbols correspond to experimental results [24] (A), [25] (B) and [26] (C) and solid lines represent the
model predictions. Top panels and bottom panels in E and F represent the experimental [22] and the predicted results, respectively. Panel D summarizes the association (k, μM−1 s−1) and
dissociation (r, 10−3 s−1) rates for dofetilide–IKr interaction, the values of clinical [23] and simulated QT intervals at 60 bpm under drug-free and under a therapeutic dofetilide dose and
the alterations introduced in the IKrmodel to simulate the effects of theN588E and N588Kmutations. In each case, ionic concentrations and temperature (37 °C, 28 °C and 22 °C for panels
A, B and C, E and F, respectively) were ﬁxed to mimic the experimental conditions. Experimental data from [22] is reproduced with permission. Experimental data from [24] (http://
onlinelibrary.wiley.com/doi/10.1113/jphysiol.2001.013296/full, DOI: 10.1113/jphysiol.2001.013296) is reproduced with permission. Experimental data from [25] is reproduced with
kind permission from Springer Science and Business Media. The onset of block by 0.5 μM dofetilide with repetitive pulsing is voltage-dependent.Two-second depolarizing pulses to –
40, 0 or +60 mV were applied with a 12-s interpulse interval (IPI). Pulses to –40 mV were applied for a longer period to allow for steady-state inhibition. All values are mean ±SEM
(n=4, 3 and 4 for –40, 0 and +60 mV respectively). Experimental data from [26] is reproduced by permission of Oxford University Press.
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We updated our previous dofetilide model [21] to additionally in-
clude the experimentally observed 70-fold preferential binding to the
inactivated state relative to the open state [22] and tomimic the clinical-
ly observed 16% prolongation of the QT interval produced by the thera-
peutic dose 8.22 nM [23] (summarized in Fig. 1D). Figs. 1 A–C show the
kinetics of the simulated (lines) IKr block by 50 nM dofetilide (A and B)
and the washout of 3 μM (C) (solid lines) together with experimental
results (symbols) for comparison: [24](A), [25] (B) and [26] (C). Proto-
cols are described in [24–26]. Figs. 1B and C show that our model also
reproduces the experimentally observed voltage dependency of the
onset of block by dofetilide [25] and the extremely slow and incomplete
dissociation of dofetilide reported by many experimental works [24,26,
27], respectively. To validate our simulations of drug interactions with
IKr, the sensitivities of two hERG mutations, N588E and N588K, to IKr
dofetilide block were also simulated. The N588E model was obtained
by modifying the rates between the open and inactivated state to pro-
duce a −36 mV shift of the conductance voltage curve (top panel ofFig. 1E) and the N588K mutation model was obtained by applying to
the human ventricular IKr model the same alterations as in [22]. Proto-
cols are described in [22]. Bottom table of Fig. 1D summarizes the mod-
iﬁcations introduced in the IKr model to simulate the effects of the
N588E and N588K mutations. The mutated residue is remote from the
drug-binding pocket in the channel pore [22], and experiments suggest
that values of drug afﬁnities for themutated IKr channels are unchanged
fromWT [22]. We also made this assumption in themodel. The top and
bottompanels of Fig. 1F include experimental data and simulation of the
Hill plots of dofetilide binding for WT, N588E and N588K, respectively.
The differential blocks in N588E and N588K mutated IKr produced by
dofetilide predicted by our model simulations are in close agreement
with the experiments performed in Chinese hamster ovary (CHO)
cells [22].
As shown in Fig. 2A, the Markov model representation of IKr from
Fink et al. includes three closed states (C3, C2 and C1), a conducting
open state (O) and an inactivation state (I). This channel model was
incorporated into the O'Hara et al. human ventricular action potential
(AP) model [14] (black traces in the top row of Fig. 3) and its maximum
Fig. 2. Fink et al. Markov model of the human IKr channels [13] (A) and simulated drug–IKr
interaction models (B, C, D, E, F) with nondrug bound and drug bound estates (d), kC, kO
and kI are the association rates constants in the closed, open and inactivated states, respec-
tively, D is the drug concentration and rC, rO and rI are the dissociation rate constants in
the closed, open and inactivated states, respectively. Binding states are red colored.
Fig. 3. Simulated steady state AP (top row), IKr (middle row) and open state probability (bot
column), deactivation (second column), inactivation (third column) and recovery from inactiv
tions. Markovian schemes of the simulated IKr mutants are depicted at the top. The orange arro
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the original O'Hara model at 1 Hz (black traces in the middle row of
Fig. 3).
We carried out “in silicomutagenesis” by modifying discrete transi-
tion rates (orange arrows in Fig. 3 model schematic) in the computa-
tional model that led to targeted modiﬁcation of channel activation,
inactivation, deactivation or recovery from inactivation (from left to
right) as indicated and resulting prolongation of the APD90 by 50 ms,
20 ms and 10 ms. These changes were intended as prototypical latent,
mild and moderate (red) allelic variants in hERG that may underlie
a predisposition to aLQTS. The effects of moderate variants led to a
50 ms APD90 prolongation (top row), IKr reduction (middle row) and
open state probability (bottom row). Deactivationmutants (second col-
umn) result in the smallest IKr among the simulated functional mutants
and with the most altered morphology (red arrow in middle row).
Deactivation mutants are most severe because IKr current arises at the
critical late juncture in the action potential to cause ﬁnal AP repolariza-
tion precisely because of the imbalance between rapid recovery from
channel inactivation and subsequent slow deactivation. This imbalance
normally results in channels residing in the open state during repolari-
zation. Mutations that increase the rate of deactivation are dire: they
lead to a marked reduction in channel open probability (red arrow in
bottom row) by promoting channel closure.
Figs. 2B–F shows the IKr Markov model described above with multi-
ple distinct drug bound conﬁgurations (lower row of states in each
panel indicated by subscript “d”) in panels B though F. Because ion
channel targeting drugs display complex properties determined by
preferential binding to distinct conformation states and/or distinct af-
ﬁnity to discrete states, we simulated a wide variety of likely combina-
tions of drug–channel interactions (Figs. 2B–F): drugs that exclusively
bound in the closed (Fig. 2B), open (Fig. 2C) or inactivated (Fig. 2D)
states, as well as drugs binding simultaneously to both the closed and
open states (Fig. 2E), or to both the open and inactivated states
(Fig. 2F), were analyzed in detail by testing a range of association and
dissociation rates for the various drug conﬁgurations. The initial esti-
mated association and dissociation rates were assumed to be similar
to the association rate of dofetilide and an intermediate value of the
dissociation rates of dofetilide. The values 0.511 μM−1 s−1 and
0.003606 s−1 were used as the baseline association and dissociation
rates. Rates were then varied in the test simulations by increasing
them 10-, 50-, or 100-fold or reducing rates 10- or 100-fold.tom row) for endocardial WT (black) and mutated cells with altered IKr activation (ﬁrst
ation (forth column) producing a 50 ms (red) APD90 prolongation under drug-free condi-
ws represent the transition rate that has been altered to simulate each mutation.
Fig. 4. Simulated steady state AP for endocardial WT (black) and mutated cells with altered IKr activation (ﬁrst column), inactivation (second column), deactivation (third column) or re-
covery from inactivation (fourth column) producing a 10ms (blue), 20 ms (green) and 50ms (red) APD90 prolongation under drug-free conditions (top row) and in the presence of low
(middle row) and high (bottom row) doses of Actilide_Oc_1 (ﬁrst and second column) or Inactilide_Oi_1 (third and fourth column) (supplementalmaterial, Table S3).Markovian schemes
of the simulated drug–channel interactions are depicted at the top. The orange arrows represent the transition rate that has been altered to simulate each mutation and the pink arrow
indicates that the drug has a high afﬁnity in that binding state.
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In the ﬁrst column of Fig. 4, the effects of latent (blue), mild (green)
and moderate (red) variants of activation (orange arrow in Markov
diagram indicates the altered transition rate) led to varying degrees of
APD90 prolongation (10, 20 and 50 ms, respectively), consistent with
the degree of change to the activation rate (ﬁrst row). We next carried
out multiple simulations with 21 IKr blocking drugs spanning a variety
of inherent kinetic properties, conformational state speciﬁcities and
concentrations. The model predicts that most drugs were unable to dif-
ferentiate between normal and mutant channels. Low doses of drugs
that exclusively bound to a single IKr state, drugs that simultaneously
bound to open and inactivated channels, and drugs that bound with
high afﬁnity to the closed state but with low afﬁnity to the open state
produced similar APD90 prolongation in normal and mutant channels.
However, themodel predicted that drugs binding to closed and open
states with higher afﬁnity to the open state (Actilide_Oc) ampliﬁedmu-
tant effects on APD90 prolongation in activation mutants compared to
WT (the pink arrow in the Markov scheme indicate a higher afﬁnity of
the drug in that state). A drug (depicted in the Markovian scheme at
the top of the ﬁrst column) with these properties was identiﬁed in the
simulations to best unmask the mutant phenotype. Exposure to 3 nM
(low dose) Actilide_Oc_1 (supplemental material, Table S3) (Fig. 4,
middle row of the ﬁrst column) increased the APD90 difference between
WT and impaired activation cells from 10 ms to 16 ms, from 20 ms to
33 ms and from 50 ms to 83 ms. Differences in APD90 between WT
and impaired activation cells were also sensitive to Actilide_Oc_1
concentration. Indeed, addition of 12 nM (high dose) Actilide_Oc_1
(Fig. 4, bottom row of the ﬁrst column) increased the APD90 differences
between WT and cells with defective activation from 10 ms to 20 ms,
from 20 ms to 43 ms and from 50 to 118 ms, respectively. Addition of
other drugs binding in the closed and open state with higher afﬁnity
to the open state (Actilide_Oc_2, Actilide_Oc_3 and Actilide_Oc_4) but
with different dissociation rates (supplemental material, Table S3) pro-
duced similar APD90 differences between WT and cells with defective
activation as Actilide_Oc_1 in the steady state. However, the durationof the transitory period from drug application to the steady state
depended on the speciﬁc association and dissociation rate values of
the drug and faster rates led to shorter transitory periods.
3.2. Latent defective deactivation
In the second column of Fig. 4, the effects of latent, mild andmoder-
ate variants of deactivation (orange arrows in theMarkov diagram indi-
cate the altered transition rate) led to corresponding varying degrees
of APD90 prolongation (ﬁrst row of the second column). We next simu-
lated the effect of a wide variety of IKr blocking drugs on these deactiva-
tion mutants. Surprisingly, the model predicts that most drugs
preferentially prolonged the steady state APD90 in mutated cells with
marked faster deactivation. This result indicates that allelic variants af-
fecting deactivation would lead to increased sensitivity to a wider
range of IKr blockers, and consequently, an increased likelihood of
aLQTS. This is in accordance with the fact that deactivation mutants
(Fig. 3, second column) result in the smallest IKr among the simulated
functional mutants and with the most altered morphology (Fig. 3, red
arrow in middle row).
Drugs binding in the closed and open stateswith signiﬁcantly higher
afﬁnity in the open state produced the largest APD90 differences be-
tween WT and mutated cells with faster deactivation, as in the case of
activation mutants, but substantially longer APD90 prolongations were
observed in deactivation mutants. The second column of Fig. 4 shows
the simulation results of exposure of deactivation mutations to one
drug of this type, Actilide_Oc_1. In this case, application of 3 nM (low
dose) Actilide_Oc_1 (Fig. 4,middle rowof the second column) ampliﬁed
the APD90 difference between WT and deactivation mutant cells from
10 ms to 113 ms (blue), from 20 ms to 181 ms (green) and from 50 to
294ms (red). Addition of 12 nM (high dose) of this drug (Fig. 4, bottom
rowof the left column) enhanced theAPD90 difference betweenWTand
deactivation mutant cells from 10 ms to 177 ms (blue) and generated
patterns of early-afterdepolarizations (EADs) in deactivation mutants
whose APD90 is 20 ms and 50 ms longer than WT under drug-free con-
ditions (green and red, respectively).
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in the open and inactivated state with a much higher afﬁnity in the
open state. Indeed, the addition of 3.6 nM (low dose) Inactilide_Oi_1
increased the APD90 differences between WT and cells with defective
deactivation from 10 ms to 102 ms, from 20 ms to 167 ms and from
50 to 262 ms (not shown). Exposure to 10.55 nM (high dose) of this
drug also further increased the APD90 differences between WT and de-
activation mutants from 10 ms to 164 ms and generated EADs in AP in
deactivation mutants whose APD90 is 20 ms and 50 ms longer than
WT under drug-free conditions (not shown). Drugs exclusively binding
in one IKr state still unmasked this type of defect in moderate mutants,
but they produced smaller APD prolongations in deactivation mutants
than the previous drugs. For example, Drug_C1 (supplementalmaterial,
Table S3) produced a 96 ms APD90 difference between WT and the de-
activation mutation cell that is 50 ms longer than WT in drug-free con-
ditions. Finally, drugs binding in the closed and open state with a much
higher afﬁnity in the closed state and drugs binding in the open and
inactivated state with a much higher afﬁnity in the inactivated state
did not help to discern between WT and mutants, as 67 ms and 64 ms
steady state APD90 differences between WT and the 50 ms APD90 pro-
longation mutation under drug-free conditions were observed during
low dose drug exposure, respectively. Again, drug-induced steady-
state APD prolongation depended on the states where the drug bound
and the preferential binding to a channel state, regardless of the diffu-
sion rate of the drug.
The previously explained ampliﬁcation of the effects of defective IKr
deactivation on APD90 prolongation produced by most drugs is directly
related to the extent of the reduction in current. Indeed, Actilide_Oc,
which is the type of drug that most ampliﬁes defective IKr deactivation
indicated by APD90 prolongation, is the one that most reduces the fast
deactivated IKr current, closely followed by Inactilide_Oi (see supple-
mental material, Fig. S2).3.3. Latent defective inactivation
The ﬁrst row of the third column of Fig. 4 shows the time course of
the APs elicited by WT and cells harboring three modeled inactivation
mutations yielding 10ms, 20ms and 50ms APD90 prolongation relative
toWT (orange arrows inMarkov diagram indicate the altered transition
rate). Our simulations predicted that low doses of simulated drugs that
bound exclusively to one discrete IKr state and drugs binding both the
closed and open state with high afﬁnity to the open state were not
able to amplify differences between WT and inactivation mutants
and were thus unable to unmask the mutations. Indeed, exposure to
10nM(lowdose) ofDrug_C1 (supplementalmaterial, Table S3) only in-
creased in 3 ms the APD90 difference between WT and the inactivation
mutantwhose APD90was 50ms longer thanWT in drug-free conditions
and Actilide_Oc_1 (supplemental material, Table S3) did not amplify it.
Drugs interacting with high afﬁnity to closed and low afﬁnity to the
open states performed somewhat better, as 750 nM (low dose) of
Actilide_Co (supplemental material, Table S3) only increased in 7 ms
the APD90 difference between WT and the inactivation mutant whose
APD90 was 50 ms longer than WT in drug-free conditions.
However, a drug with high afﬁnity open state block (pink arrow in
model schematic) and lower afﬁnity inactivated state (black arrow)
very effectively unmasked IKr mutants causing impaired inactivation.
Speciﬁcally, application of 3.6 nM (low dose) and 10.55 nM (high
dose) Inactilide_Oi_1 (supplemental material, Table S3) (Fig. 4, middle
and bottom row of the third column, respectively) enhanced the
APD90 differences between WT and defective inactivation cells from
10 ms to 15 ms and 19 ms (blue), from 20 ms to 28 ms and 39 ms
(green) and from 50 to 76 ms and 113 ms (red), respectively. In this
case, the steady state APD prolongation observed during drug exposure
also dependedmost on the states where the drug bound and the prefer-
ential binding state regardless of its diffusion rate.3.4. Latent defective recovery from inactivation
Low doses of each drug were applied to WT and cells containing a
simulated mutagenesis affecting the rate constant controlling IKr recov-
ery from inactivation (RFI, rate from I to O) indicated by the orange
arrow in the schematic. Simulated mutations yielded 10 ms, 20 ms
and 50 ms APD90 prolongation compared to WT (Fig. 4, ﬁrst row of
the fourth column). As expected, this simulated defect primarily affect-
ed the fractions of channels in the inactivated and open state, much like
mutations that affected the inactivation transition. A drug with prefer-
ential high afﬁnity block in the open state (pink arrow) and lower afﬁn-
ity block in the inactivated state (black arrow) as depicted in the
Markovian scheme at the top of the fourth column of Fig. 4, ampliﬁed
the mutation effect, observed by more APD90 prolongation in mutated
cells with impaired recovery from inactivation than in WT cells. In this
case, application of 3.6 nM (low dose) and 10.55 nM (high dose)
Inactilide_Oi_1 (Fig. 4, middle and bottom rows of the fourth column,
respectively) augmented the APD90 difference between WT and RFI
mutant cells from 10 ms to 15 ms and 18 ms (blue), from 20 ms to
27 ms and 37 ms (green) and from 50 to 76 ms and 99 ms (red),
respectively.
3.5. M54T hMiRP1 mutation
We also applied this procedure to the naturally occurring hERG
mutation, the M54T MiRP1 mutation, which has been implicated in
drug-induced LQTS and arrhythmia [1,4]. Fig. 5 compares the experi-
mental (top row) and the simulated (bottom row) steady state activa-
tion curve (left column) and the deactivation time constant curve
(right column) for WT (squares) and M54T hMiRP1 mutated channels
(triangles). Protocols are described in Abbott et al. [4]. This mutation is
known to moderately increase the voltage dependence of activation
by reducing the activation slope without altering the half activation po-
tential [4]. The experimentally measured activation slope was 9.5 mV
and 7.5 mV for WT and M54T hMiRP1 mutated channels, respectively
[4]. Therefore, the activation slope of these mutated channels is 75.8%
the slope of the WT channels. The activation slope of the simulated
M54T hMiRP1 mutated channels is 75.5% the slope of the simulated
WT channels. Importantly, M54T hMiRP1 mutated channels are also
known to deactivate approximately twice as fast asWT [4]. Our simulat-
ed M54T hMiRP1 mutated channels reproduce this alteration (right
panels). In addition, experimental results evidence that M54T hMiRP1
mutated channels were like wild type in their steady state inactivation
[4]. The simulated M54T hMiRP1 mutation did not alter the steady
state inactivation curve in ourmodel (not shown). Moreover, additional
experiments reported a reduction of 39% in current density at−40mV
in M54T hMiRP1 mutated channels [1]. The alteration of the transition
rates in our simulatedM54T hMiRP1mutated channels caused a similar
reduction in current density (not shown), therefore themaximum con-
ductance of the mutated channels was not modiﬁed. Rate constants for
the simulatedM54T hMiRP1 channels are provided in the supplemental
material (Table S2). Quantitative differences between the experimental
results of the M54T MiRP1 latent mutation and the simulations (Fig. 5)
derive from the differences in the cells and subunits of the channels
used in the characterization of the mutation and the data used to
model the IKr used in our study. Indeed, the experimental data (shown
in the top row of Fig. 5) was obtained from hMiRP1/hERG channels
expressed in Xenopus laevis oocytes [4] and the IKr model proposed by
Fink et al. [13] and used in our simulations for WT cells was ﬁtted to
experimental data from hERG in HEK cells and humanmyocytes and in-
corporated relative changes resulting from the mutation into the base-
line Fink model.
We incorporated theM54T hMiRP1 channels into the APmodel. The
M54T hMiRP1 mutated (orange) APD90 was 11.6 ms longer than WT
(black) APD90 in isolated endocardial cells (Fig. 6A). As we did with
the virtual mutations, we also observed the ampliﬁcation of the APD90
Fig. 5. Experimental (top panels) [4] and simulated (bottom panels) steady-state activation (A and C) and deactivation time constants for WT (squares) and M54T hMiRP1 mutated
(triangles) channels at 22 °C. Top panels are reprinted from [4] with permission from Elsevier.
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exposure. The virtual drug types that most ampliﬁed the APD90 of
M54T hMiRP1 mutants were Actilide_Oc and Inactilide_Oi. Speciﬁcally,
low doses of both Actilide_Oc_2 and Inactilide_Oi_2 led to a 46 ms dif-
ference between M54T hMiRP1 mutants and WT cells. Addition of
other types of drugs did not help to differentiate between M54T
hMiRP1 mutants and WT cells. For example, exposure to low dose of
Drug_C_2 only produced 3 ms additional difference in APD90 between
M54T andWT cells compared to drug-free conditions. These results re-
sembled those obtained with the prototypical latent fast deactivation
mutant. It supports the validity of our method to predict the drug
types that affect a particular mutation, as fast deactivation is the main
IKr alteration produced byM54T hMiRP1mutation [4]. We also simulat-
ed the effects of the real drug dofetilide in the presence of this naturally
occurring mutation. Exposure to 16 nM (low dose) and 48 nM (high
dose) dofetilide increased the APD90 difference between WT (black)
and mutants (orange) from 11.5 ms (Fig. 6B) to 46 ms (Fig. 6C)
and 65 ms (Fig. 6D), respectively. It is notable that dofetilide and
Inactilide_Oi_2 produced similar results. Dofetilide could be classiﬁed
as an Inactilide_Oi drug because it binds in the open and in theFig. 6. Simulated steady state AP of isolated endocardial cells (top row) and pseudo-ECG (bottom
in the presence of 16 nM(lowdose) and 48 nM(high dose) of dofetilide (middle and left colum
the mutated transmural wedge preparation.inactivated states [25] with a 70-fold preferential binding to the
inactivated state relative to the open state [22].
As the ECG is the electrical signal used for clinical diagnosis rather
than the APD in isolated cells, we also simulated the pseudo-ECG
using a 1-dimensional model of the transmural wedge to investigate
the potential use of this dofetilide modiﬁcation to unmask silent muta-
tion carriers. Our results (Fig. 6, bottom row) show that the M54T
hMiRP1mutation produced a 6ms prolongation of the simulated QT in-
terval duration (WT QT interval duration = 392 ms, Fig. 6D) under
drug-free conditions. The presence of 16 nM (low dose) and 48 nM
(high dose) of dofetilide ampliﬁed the QT interval duration difference
betweenWT andmutant to 47ms (Fig. 6E) and 105ms (Fig. 6F), respec-
tively. The generation of EADs in midmyocardial cells (see inset of
Fig. 6F) in the transmural strand after the application of high dose
modiﬁed dofetilide led tomore aggravated differences in theQT interval
between WT and M54T mutated cells than in the APD90 registered in
isolated cells. The development of the EAD in the M cell only leads to
an apparent increase in dispersion of repolarization, observed on
the simulated ECG as a broadening of the t-wave (due to very long
repolarization in the M-cell) and also an increase in the amplitude ofrow) forWT (black) andM54T hMiRP1 cells (orange) in the absence (right column) and
n, respectively). Inset of panel F shows theAP ofmidmyocardial cell #85 of the 1Dmodel of
Fig. 7. Simulated steady state AP for endocardial WT (black) andM54T hMiRP1 cells (orange) in the absence (thin) and in the presence (thick) of real (top row) and prototypical (bottom
row) IKr activators under different conditions: in the presence of low dose (16 nM) dofetilide (ﬁrst column) and under IKr blocker drug free conditions (middle and last column). IKr
activator dose is indicated in each panel.
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occurs when the epicardial cell has repolarized and the M-cell is
depolarized due to the EAD.
Simulated pseudo-ECGs at 1 Hz forWT in the presence of high doses
of every drug considered in this study are shown in Fig. S5 in the supple-
mentalmaterial. Although they are very similar, small differences in the
T-wave are observed. Indeed, the drugs that most increase the ampli-
tude of the T-wave are Inactilide_Oi, Inactilide_Io and Actilide_Co,
followed by drugs binding and unbinding in one state of the channel
(Drug_C, Drug_O and Drug_I). Actilide_Oc caused minimal increase in
the amplitude of the T-wave (see Fig. S6 in the supplemental material).
We also simulated the addition of potassium channel activators to
mitigate the effects of dofetilide exposure on M54T hMiRP mutated
channels to dramatically prolong APD90. AsM54T hMiRPmutated chan-
nels exhibit fast deactivation, our analysis suggests that a channel open-
er that slows deactivation would be postulated as the ideal channel
opener. Therefore, type 1 agonists, which slow deactivation and attenu-
ate inactivation, would be more appropriate in this case than type 2
agonists, which attenuate inactivation without slowing deactivation
[28]. Fig. 7A shows that addition of 230 nM RPR260243 (orange thick
line), a type 1 agonist, following application of 16 nM dofetilide in
M54T hMiRP1 mutated cells at 1 Hz (orange thin line) shortened
APD90 to the level observed in WT cells in the presence of 16 nM
dofetilide at 1 Hz (black thin line). In other words, adjunctive therapy
with a type 1 hERG channel activator canceled the effects of the M54T
mutation. This was also observed at 0.67 Hz and 2 Hz (2.3 ms and
7.8 ms APD90 difference, respectively). Importantly, the reduction in
APD90 predicted by the model simulations in both WT and M54T
hMiRPmutated cells in the presence of 230 nMRPR260243was compa-
rable (~26 ms, see Fig. 7B at 1 Hz) and the shortening was dose-
dependent (see Figs. 7B and C at 1 Hz). This prediction suggests that
the type 1 hERG channel activator did not discriminate between WT and
mutant channels, suggesting that the drug would not cause
unexpected effects through interaction with the mutation.
Next, we used our in silicomethod to predict properties to improve
the performance of this activator. Our simulations suggest that elimina-
tion of the effects of RPR260243 on inactivation (RPR260243_mod)
would minimize the shortening of the APD90 in the absence of IKr
blockers while reducing the APD90 prolongation of M54T hMiRP1 mu-
tated cells and the related in silicomutant in the presence of dofetilide.
Indeed, addition of 1.2 mM RPR260243_mod to 16 nM dofetilide in
M54T hMiRP1 mutated cells normalized APD90 to WT in the presence
of 16 nM dofetilide at 1 Hz (Fig. 7D), 0.67 Hz and 2 Hz (0.7 ms, 1.5 ms
and 18.4 ms APD90 difference, respectively). Importantly, this concen-
tration of RPR260243_mod did not reduce the APD90of WT and M54ThMiRP1 mutated cells in the absence of dofetilide(Fig. 7E), except for
a small 4 ms reduction at 2 Hz. In addition, a ten-fold increase in
RPR260243_mod concentration did not reduce the APD90 of WT
cells in the absence of dofetilide at 1 Hz (Fig. 7F) and only reduced
it in 6 ms at 2 Hz. Similar results were obtained when these channel
openers were added to in silico mutated cells with hastened
deactivation.
3.6. Effects of heart rate and combination of mutations
To further investigate the genetic predisposition to aLQTS, the inﬂu-
ence of heart rate and the presence of silent mutations on other ionic
currents were also analyzed.
3.6.1. Heart rate
We next tested the rate dependence of pharmacological ampliﬁca-
tion of IKr allelic variants on APD90 during exposure to the drugs that
most ampliﬁed them at 1Hz (Actilide_Oc, Inactilide_Oi and drugs exclu-
sively binding and unbinding in the closed, open or inactivated states).
Drugs were tested at fast (2 Hz) and slow frequencies (0.67 Hz). Fig. 8
shows the rate dependence of the effects of activation (A), deactivation
(B), inactivation (C) and recovery from inactivation (D) Ikr mutants pro-
ducing a 50 ms prolongation of APD90 under drug-free conditions at
1 Hz on AP90 under drug-free conditions (black) and under exposure
to low dose Actilide_Oc_1 (red), Inactilide_Oi_1 (green), and Drug_C1
(blue). Our simulations show that the same drugs that ampliﬁedmutant
effects on APD90 prolongation at 1 Hz also ampliﬁed them at fast and
slow frequencies, although the magnitude of the APD90 prolongation
depended on the type of the drug, themutant and the heart rate. In gen-
eral, the slower the frequency, the larger the mutant ampliﬁcation on
APD90 predicted. As observed at 1 Hz, APD90 of deactivation mutants
were preferentially prolonged by most drugs, especially by Actilide_Oc
and Inactilide_Oi. Low doses of these drugs produced EADs at 0.67 Hz
and APD90 longer than 500 ms at 2 Hz (Fig. 8B). Drugs binding in only
one state also enhanced the APD differences between deactivation
mutants and WT, although to a lesser extent (Fig. 8B). In addition, the
effects of impaired activation on APD90 were especially ampliﬁed
under exposure to Actilide_Oc, regardless of the pacing rate (Fig. 8A).
Finally, Inactilide_Iowas the type of drug thatmost ampliﬁed inactivation
and recovery from inactivation mutant effects on APD90 prolongation at
all frequencies (Figs. 8C and D).
Differences between WT cells and IKr mutants on APD heart rate
adaptation to abrupt changes in pacing frequency under drug-free con-
ditions and under exposure to selected IKr–drug interactions were also
investigated (see supplemental material, Fig. S3 and Table S4). WT
Fig. 8. Rate dependence of the effects of IKr mutants on ADP90 under drug-free conditions (black) and under exposure to low doses of those drugs that signiﬁcantly amplify them, namely
Actilide Oc_1 (red), Inactilide_Oi_1 (green) and Drug_C1 (blue) (supplemental material, Table S3). ADP90 differences between WT cells and mutated cells with altered IKr activation
(A), deactivation (B), inactivation (C) and recovery from inactivation (D) producing a 50 ms (red) APD90 prolongation under drug-free conditions at 1 Hz. ADP90 differences between
WT cells and mutated cells with altered IKr deactivation under exposure to low doses of Actilide Oc_1 (red) and Inactilide_Oi_1 (green) at 2 Hz is not shown as mutated cells were stim-
ulated before the repolarization process was completed. Markovian schemes of the simulated IKr mutants are depicted at the top. The orange arrows represent the transition rate that has
been altered to simulate each mutation.
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pacing rates under drug-free conditions as observed experimentally.
Notably, the simulated time constants (shown in Fig. S3 and Table S4)
were close to the values experimentally recorded [17,20] and simulated
in other works [19,20]. The biggest differences betweenWT cells and IKr
mutants on APD adaptation to abrupt changes in pacing rate under drug
exposure were found in τslow_decelarating and τslow_accelarating under
Inactilide_Oi_1 exposure, specially between WT cells and activation IKr
mutants (see supplemental material, Fig. S3 and Table S4).
3.6.2. Combination with other silent mutations
APD90 of control cells and IKr mutants under drug free conditions
were prolonged in the presence of IKs or INaL silent mutations, although
the extent of APD90 prolongation depended on the speciﬁc combina-
tion of mutations. Indeed, APD90 of activation, deactivation, inactiva-
tion and recovery from inactivation IKr mutants whose APD90 was
50 ms longer than WT under drug-free conditions exhibited a
18 ms, 24 ms, 29 ms and 29 ms prolongation in the presence of IKs
silent mutations and a 18 ms, 25 ms, 25 ms and 25 ms prolongation
in the presence of INaL mutations, respectively (see supplemental
material, Fig. S4).
Ampliﬁcation of the effects of IKr mutants on APD90 under drug ex-
posure was further enhanced when IKr mutants were combined with
IKs or INaL mutations, although INaL silent mutations exerted a smaller
inﬂuence (Fig. S4 and Table S5). Importantly, deactivation defectivemu-
tants in combination with IKr and INaL silent mutations routinely devel-
oped EADs under exposure to lowdoses of Actilide_Oc and Inactilide_Oi
(Fig. S4). It is to be noted that Inactilide_Oi ampliﬁed the effects of im-
paired inactivation and recovery from inactivation IKr in APD90 prolon-
gation much more effectively in combination with latent IKs mutants
(Fig. S4). Indeed, 3.6 nM (low dose) of Inactilide_Oi_1 prolonged the
effects of IKr inactivation and recovery from inactivation mutants on
APD90 prolongation from 50 ms to 73 ms in the absence of IKs latentmutants (Fig. 4) and from 49 ms to 96 ms in the presence of IKs latent
mutants (Fig. S4). The bigger inﬂuence of IKs silent mutants on the ef-
fects of defective IKr on APD90 than INaL silent mutants may be related
to the fact that both IKr and IKs contribute to the repolarization reserve
of the cells, so a reduction of both currents can create a synergistic effect
on APD90 prolongation.
4. Discussion
4.1. Main ﬁndings
We used a computational approach to identify characteristics of
drugs that selectively unmask latent, mild and moderate IKr mutations.
The simulations predicted that drugs exhibiting low afﬁnity closed-
state and high afﬁnity open-state block (Actilide_Oc) or low afﬁnity
inactivated-state and high afﬁnity open-state block (Inactilide_Oi) un-
mask aLQTS arising from IKr gene variants. Exposure to such drugs
caused dramatic APD prolongation in the setting of mutations causing
faster IKr deactivation. By contrast, cells with impaired activation were
predicted to develop the longest APDs following exposure to drugs
exhibiting low afﬁnity closed-state binding and high afﬁnity open
state block (Actilide_Oc). Addition of drugs with other properties to
cells with impaired activation produced less APD prolongation. Defects
in channel inactivation and recovery from inactivation were revealed
with drugs exhibiting low afﬁnity inactivated-state binding and high
afﬁnity open-state block (Inactilide Oi) while they were hidden under
exposure to other types of drugs. Importantly, our method could be
expanded and used to predict which type of drug would most affect
any characterized IKr mutation. We have constructed a comprehensive
library of mutant and drug interaction templates that can be readily
modiﬁed to predict interactions of interest.
To our knowledge, this is the ﬁrst time that a provocative test has
been shown to selectively differentiate mutations in an ionic channel.
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a proof of concept for future provocative tests in IKr and for the design of
provocative tests in other ionic currents.
Our results suggest the speciﬁc properties of IKr blocking drugsmost
likely to cause aLQTS and amplify the impact of allelic variants in IKr
genes in those at risk of development of drug-induced arrhythmias.This
study reinforces a widely understood concept−that not all IKrblock is
the same. But, our results also suggest speciﬁc properties of IKrblock
that should be included in pre-clinical screening to ensure cardiac
safety of all commercial therapeutics. Our study strongly suggests
that an observation of a reduction of current comprises insufﬁcient in-
formation to evaluate cardiac safety: screening must include kinetic
measurements of hERG block.4.2. Latent mutations
Despite the work done on the identiﬁcation of proarrhythmic risk
factors, prediction of the development of arrhythmic episodes in an in-
dividual subject remains unattainable [29]. It iswell-known that genetic
factors may increase the proarrhythmic risk, however, the importance
of altered gene expression in drug-induced TdP development is not
clear [29]. Our work intends to begin to shed light on these questions
and it could be used to predict the characteristics of the drugs that are
more proarrhythmic in the presence of any characterized IKr mutation.
In our simulations the longest drug-induced APD prolongations were
observed in deactivation mutated cells (Fig. 3, second column) and
most prototypical drugs preferentially prolonged APD in deactivation
mutants than in WT cells, especially Actilide_Oc and Inactilide_Oi,
dofetilide being notably similar to the latter. Clinical and experimental
observations relating accelerated deactivation to aLQTS support our re-
sults. One patient with normal QT interval that suffered procainamide-
induced arrhythmia had the M54T-hMiRP1 mutation that accelerates
deactivation [1], which has been also observed in one patient among
230 patients with sporadic LQTS but not in 1010 controls [4]. Our
study suggests that this latentmutation is prone to develop aLQTS espe-
cially under provocation with dofetilide-like drugs and Actilide_Oc. In
addition, the S706F/KCNH2 and M756V/KCNH2 mutations have been
associated to aLQTS [30]. These mutations accelerate channel deactiva-
tion and inactivation and alter the steady state inactivation curve [30].
Our study suggests that these alterations on IKr kinetics could lead to
aLQTS especially in the presence of Inactilide_Oi (like dofetilide), as ob-
served in the virtual inactivation, recovery from inactivation and deacti-
vationmutants, and Actilide_Oc, similar to the prototypical deactivation
mutants. In addition, the A561P hERGmutation, which signiﬁcantly ac-
celerates the deactivation and shifts the steady state activation curve,
has been linked to LQTS and clobutinol-induced arrhythmic episodes
[31]. The alterations in deactivation and activation kinetics produced
by this mutation also suggest a preferential prolongation of the APD in
the presence of Actilide_Oc and Inactilide_Oi.
Other IKr kinetic defects have also been implicated in aLQTS and
arrhythmias, consistent with our predictions of APD prolongation
resulting from altered activation, inactivation and recovery from inacti-
vation in the presence of certain drugs (Fig. 4, ﬁrst, third and fourth
column). In principle, our work suggests that these mutations would
be less proarrhythmic than deactivation mutants, although it also de-
pends on the severity of the IKr alterations. The D342V/KCNH2 and
H492Y/KCNH2 mutations mostly alter inactivation kinetics and have
been associated with aLQTS [30]. According to our study, only analogs
of drugs like Inactilide_Oi and dofetilide, would amplify the effects
of these mutants. As previously mentioned, the S706F/KCNH2 and
M756V/KCNH2 in addition to accelerating deactivation also accelerate
inactivation [30]. Moreover, the polymorphism R104L in hERG causes
defects in activation and inactivation and has been related to the inci-
dence of TdP induced by dofetilide [32]. Indeed, our study suggests
that Inactilide_Oi, like dofetilide, and Actilide_Oc could signiﬁcantlyprolong the APD in this mutation due to its defective inactivation and
activation, respectively.
4.3. Provocative tests
Potent sodium blockers, like ﬂecainide, have been used to unmask
Brugada syndrome in patients with concealed forms of the disease [9].
More recently, a combined sodium and calcium block has been shown
to bemore effective for revealing this disease [10]. In addition, epineph-
rine and isoproterenol, which enhance beta-adrenergic stimulation,
unmasked some silent LQT1 mutation carriers [8,33]. Sotalol, a potent
IKr blocker, has been shown to uncover altered repolarization [11],
while another, erythromycycin, prolonged the T peak-to-end interval
in LQT2 mutations, causing only modest QT prolongation in LQT1 and
LQT2 mutations with normal QT interval [12]. In the aforementioned
works drugs were used to reveal the genetic defects by reducing the
repolarization reserve. However, in our study IKr–drug interactions are
designed to reveal the speciﬁc impaired IKr kinetics. Our results indicate
that unmasking of speciﬁc impaired IKr kinetics would be possible using
drugs with disparate afﬁnities in the binding states of the IKrchannel. Our
results suggest that dofetilide could be used to unmask defects in chan-
nel deactivation, inactivation and recovery from inactivation as it ex-
hibits low afﬁnity inactivated-state binding and high afﬁnity open-
state block (Inactilide_Oi).
When a drug exhibits variable state afﬁnity, the extent of IKr reduc-
tion depends on the afﬁnity of the drug in each state and the probability
of residency of the channel in conformations where the drug interacts.
Therefore, a mutation increasing the probability of the state where the
drug is more potent will favor the block of the channel while a genetic
defect decreasing that probability would minimize the block. Impor-
tantly, this mechanism could also permit the selective unmasking of
silent mutations of other ionic currents, such as INa or IKs, which would
improve diagnostic of all types of LQTS and, subsequently, the therapy
of the LQTS.
Major advances in the pharmacological ﬁeld have occurred includ-
ing the automated patch-clamp, which allows high-throughput com-
pound screening [34]. In addition, molecular modeling techniques
have been implemented for the assessment of the blocking ability of
drugs to the hERG1 pore domain [35]. Moreover, crystal structures of
different conformational states of a K+ channel in bacteria have been
identiﬁed [36], which would allow the estimation of the differences of
drug afﬁnity in the different states of the channel. These and other
newadvances could be used in combinationwith our computational ap-
proach for drug and disease screening and identiﬁcation and production
of drugs or small molecules for provocative tests.
4.4. Drug safety
Our results indicate that drugswith disparate afﬁnities to conforma-
tional states aremore likely to amplify APDdifferences betweenWT and
mutated cells than drugs with similar afﬁnities to all states. Examples of
drugs with disparate afﬁnities to conformational states and related to
drug-inducedQT prolongation and arrhythmia are dofetilide (which ex-
hibits a 70-fold preferential binding to the inactivated state relative to
the open state), astemizole, cisapride, dl-sotalol, and terfenadine [22].
Our results also suggest that exactly these kinds of drugs should be
avoided in pharmacological therapies or accompanied by IKr openers,
as they could favor the appearance of aLQTS and arrhythmias in patients
with common allelic variants in genes encoding the proteins constitut-
ing IKr. Therefore, the relative potency of block in the states that the drug
interacts with the channels should be measured in the process of pre-
clinical drug screening. Indeed, our simulations suggest that if these
potencies were realized in the preclinical screen, then appropriate
adjunctive therapy with a hERG channel activator could be employed
to cancel any additive effects of a mutation.
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degree of blockade of IKr [3,29]. Pharmacokinetic–pharmacodynamic
relationships are known to be relevant for the development of TdP [29].
In this study, we show that the kinetics of block is crucial for amplifying
the kinetic defects of the channel that prolong the APD, which may
favor the generation of arrhythmias.4.5. Limitations
In this work we used the same values of drug afﬁnities for WT and
mutated IKr cells. Severe mutations themselves can, however, modify
the afﬁnity of the drug [27] by indirect allosteric modiﬁcations in the
structure of the channel protein [27]. The subtlemutations, as simulated
here, would not be expected to signiﬁcantly modify the structure of the
channel. It is also worth mentioning that some IKr blocking drugs have
been shown to modify channel trafﬁcking [37]. In this paper, this effect
has not been speciﬁcally taken into account, but would be interesting
to consider with sufﬁcient data to inform the model in future studies
[37].
In this study a wide variety of virtual drugs has been simulated in
order to predict the most potentially lethal combinations of drug
properties and IKr kinetic abnormalities. Our results show that ampli-
ﬁcation of IKr kinetic defects on APD is observed under exposure to
drugs with disparate afﬁnities to conformational states of the IKr
channel because of the differences in the residence of the channels
in the binding states between the mutated and WT channels. Our
study could be extended by considering an almost inﬁnite possibility
of additional virtual drugs, for example drugs with varying afﬁnities
to discrete closed states. Tools utilized in this study for simulating
the effects of drugs and mutations on AP will be available upon
request.
Finally, our in silico simulation approach allows investigations that
would be difﬁcult to undertake in vitro, such as precise kinetic drug
properties and mutations, and the use of human cells. Our model of IKr
drug interaction has been experimentally validated as it successfully
reproduced drug sensitivities of two hERG mutations, N588E and
N588K, to IKr dofetilide block. Although it is outside of the scope of
this paper, the performance of experiments to compare drug block for
WT and KCNE2 mutants at different dofetilide concentrations would
be also interesting. These experiments could also be used to validate
Markov simulations of channel block.Disclosure statement
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